0.93
+0.0493(+5.60%)
Currency In USD
| Previous Close | 0.88 |
| Open | 0.89 |
| Day High | 0.94 |
| Day Low | 0.85 |
| 52-Week High | 2.12 |
| 52-Week Low | 0.8 |
| Volume | 566,408 |
| Average Volume | 727,996 |
| Market Cap | 70.46M |
| PE | -2.06 |
| EPS | -0.45 |
| Moving Average 50 Days | 1.06 |
| Moving Average 200 Days | 1.22 |
| Change | 0.05 |
If you invested $1000 in Clearside Biomedical, Inc. (CLSD) since IPO date, it would be worth $128.14 as of December 26, 2024 at a share price of $0.929. Whereas If you bought $1000 worth of Clearside Biomedical, Inc. (CLSD) shares 5 years ago, it would be worth $273.24 as of December 26, 2024 at a share price of $0.929.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Clearside Biomedical Announces Publication of Critical Insights into Retinal Drug Development in the Peer-Reviewed Scientific Journal, Eye
GlobeNewswire Inc.
Dec 19, 2024 12:05 PM GMT
ALPHARETTA, Ga., Dec. 19, 2024 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (Nasdaq: CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space (SCS®), announced today that
Clearside Biomedical Extends Global Footprint with Numerous Presentations at Medical Meetings in Asia, Europe and the United States
GlobeNewswire Inc.
Nov 25, 2024 12:05 PM GMT
- Commercial, Clinical and Regulatory Expertise Establish Clearside as the Leader in Suprachoroidal Delivery - - Multiple Events at Asia-Pacific Vitreo-Retina Society Congress Highlighting Clearside’s Pipeline Programs and Suprachoroidal Delivery Tec
Clearside Biomedical Partner Arctic Vision Executes Commercial Collaboration Agreement with Santen Pharmaceutical Co., Ltd for ARVN001 Suprachoroidal Space Injection Therapy for the Treatment of Uveitic Macular Edema
GlobeNewswire Inc.
Nov 07, 2024 2:05 PM GMT
- Partnership Creates New Opportunities to Address Unmet Needs Related to Posterior Segment Eye Diseases in China - - Agreement Provides Additional Validation for Clearside’s Suprachoroidal Space (SCS®) Delivery Platform - ALPHARETTA, Ga., Nov. 07,